Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis

Clin Lung Cancer. 2020 Jan;21(1):e6-e9. doi: 10.1016/j.cllc.2019.09.005. Epub 2019 Sep 26.
No abstract available

Keywords: Atezolizumab; Immunotherapy; Nivolumab; PD-1; PD-L1.

MeSH terms

  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects
  • Dermatitis / etiology
  • Dermatitis / pathology*
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Drug-Related Side Effects and Adverse Reactions / pathology*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / pathology
  • Middle Aged
  • Neoplasm Staging
  • Nivolumab / administration & dosage*
  • Nivolumab / adverse effects
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology
  • Small Cell Lung Carcinoma / drug therapy*
  • Small Cell Lung Carcinoma / immunology
  • Small Cell Lung Carcinoma / pathology
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab